Clinical Trials for Mesothelioma Patients—Gene Therapy for Pleural Malignancies

Read about a current clinical trial on gene therapy being conducted on patients with advanced cancer or malignant mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. This trial is currently only being conducted in Switzerland.

Gene Therapy for Pleural Malignancies

Purpose

This Phase I study will evaluate the safety of two doses of BG00001. Eligible subjects will have:

• malignant pleural mesothelioma, or
• pleural effusions who have progressed through at least one prior therapy or have refused therapy

BG00001 is given twice, on Day 1 and Day 15. BG00001 is given through a catheter in the pleural space.

Phase, Condition and Intervention

Phase I; Pleural Mesothelioma, Metastatic Pleural Effusions; Gene Transfer: BG00001 (adenoviral-mediated interferon-beta)

Study Type and Design

Interventional; Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety Study

Official Title:

A Phase I Clinical Trial of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-Beta (BG00001, Ad.hIFN-ß for Pleural Malignancies